TY - JOUR
T1 - Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma
T2 - Preliminary Experience
AU - Dwivedi, Durgesh K.
AU - Xi, Yin
AU - Kapur, Payal
AU - Madhuranthakam, Ananth J.
AU - Lewis, Matthew A.
AU - Udayakumar, Durga
AU - Rasmussen, Robert
AU - Yuan, Qing
AU - Bagrodia, Aditya
AU - Margulis, Vitaly
AU - Fulkerson, Michael
AU - Brugarolas, James
AU - Cadeddu, Jeffrey A.
AU - Pedrosa, Ivan
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - Introduction: Percutaneous renal mass biopsy results can accurately diagnose clear cell renal cell carcinoma (ccRCC); however, their reliability to determine nuclear grade in larger, heterogeneous tumors is limited. We assessed the ability of radiomics analyses of magnetic resonance imaging (MRI) to predict high-grade (HG) histology in ccRCC. Patients and Methods: Seventy patients with a renal mass underwent 3 T MRI before surgery between August 2012 and August 2017. Tumor length, first-order statistics, and Haralick texture features were calculated on T2-weighted and dynamic contrast-enhanced (DCE) MRI after manual tumor segmentation. After a variable clustering algorithm was applied, tumor length, washout, and all cluster features were evaluated univariably by receiver operating characteristic curves. Three logistic regression models were constructed to assess the predictability of HG ccRCC and then cross-validated. Results: At univariate analysis, area under the curve values of length, and DCE texture cluster 1 and cluster 3 for diagnosis of HG ccRCC were 0.7 (95% confidence interval [CI], 0.58-0.82, false discovery rate P = .008), 0.72 (95% CI, 0.59-0.84, false discovery rate P = .004), and 0.75 (95% CI, 0.63-0.87, false discovery rate P = .0009), respectively. At multivariable analysis, area under the curve for model 1 (tumor length only), model 2 (length + DCE clusters 3 and 4), and model 3 (DCE cluster 1 and 3) for diagnosis of HG ccRCC were 0.67 (95% CI, 0.54-0.79), 0.82 (95% CI, 0.71-0.92), and 0.81 (95% CI, 0.70-0.91), respectively. Conclusion: Radiomics analysis of MRI images was superior to tumor size for the prediction of HG histology in ccRCC in our cohort.
AB - Introduction: Percutaneous renal mass biopsy results can accurately diagnose clear cell renal cell carcinoma (ccRCC); however, their reliability to determine nuclear grade in larger, heterogeneous tumors is limited. We assessed the ability of radiomics analyses of magnetic resonance imaging (MRI) to predict high-grade (HG) histology in ccRCC. Patients and Methods: Seventy patients with a renal mass underwent 3 T MRI before surgery between August 2012 and August 2017. Tumor length, first-order statistics, and Haralick texture features were calculated on T2-weighted and dynamic contrast-enhanced (DCE) MRI after manual tumor segmentation. After a variable clustering algorithm was applied, tumor length, washout, and all cluster features were evaluated univariably by receiver operating characteristic curves. Three logistic regression models were constructed to assess the predictability of HG ccRCC and then cross-validated. Results: At univariate analysis, area under the curve values of length, and DCE texture cluster 1 and cluster 3 for diagnosis of HG ccRCC were 0.7 (95% confidence interval [CI], 0.58-0.82, false discovery rate P = .008), 0.72 (95% CI, 0.59-0.84, false discovery rate P = .004), and 0.75 (95% CI, 0.63-0.87, false discovery rate P = .0009), respectively. At multivariable analysis, area under the curve for model 1 (tumor length only), model 2 (length + DCE clusters 3 and 4), and model 3 (DCE cluster 1 and 3) for diagnosis of HG ccRCC were 0.67 (95% CI, 0.54-0.79), 0.82 (95% CI, 0.71-0.92), and 0.81 (95% CI, 0.70-0.91), respectively. Conclusion: Radiomics analysis of MRI images was superior to tumor size for the prediction of HG histology in ccRCC in our cohort.
KW - First-order statistics
KW - Gray level co-occurrence matrix
KW - Kidney cancer
KW - Texture analysis
KW - Tumor heterogeneity
UR - http://www.scopus.com/inward/record.url?scp=85087821026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087821026&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2020.05.011
DO - 10.1016/j.clgc.2020.05.011
M3 - Article
C2 - 32669212
AN - SCOPUS:85087821026
SN - 1558-7673
VL - 19
SP - 12-21.e1
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 1
ER -